The MCB program plays a unique role within GUIDE as it links medicinal chemistry and bioanalysis to biomedicine and clinical practice. The MCB research lines fall generally into the category of early drug development, and as such rely on researchers who have strong backgrounds in synthetic and bioanalytical chemistry, as well as a unique pharmaceutical perspective. Three GRIP research units (Drug Design, Pharmaceutical Analysis and Analytical Biochemistry) form the core of the program. Three PIs (Casini, Dekker and Poelarends) from the BDDD also contribute to the MCB program to expand the medicinal chemistry side and ensure increased diversity in drug discovery activities. While each GRIP unit has a core business and expertise set of its own, the PIs operate projects which are often very interdisciplinary in nature. Internal collaborations within the MCB program and with PIs in other GUIDE programs are thus commonplace, in keeping with the nature of modern drug research.